SecBot SecBot
SECBOTREPLAY Home › Report › PHVS

PHVS · Pharvaris filed a prospectus supplement for an underwritten public…

Pharvaris N.V. · 424B5 filed May 8, 2026 at 17:13 ET

At the news

NEUTRALIMPACT 4/10

424B5 filed May 8, 2026 at 17:13 ET

Pharvaris filed a prospectus supplement for an underwritten public offering of 3,874,664 ordinary shares at $29.68 per share, with an option for an additional 581,199 shares. The offering is expected to raise approximately $107.5 million in net proceeds (or $123.7 million if the option is fully exercised), which will be used to fund late-stage clinical programs, US commercialization efforts, and working capital. The company reported $247 million in cash as of March 31, 2026, and the offering extends its runway into the first half of 2028.

  • Offering 3,874,664 shares at $29.68 per share, total gross proceeds of $115 million
  • Underwriters have a 30-day option to purchase up to an additional 581,199 shares
  • Net proceeds estimated at $107.5 million ($123.7 million with option exercise)
  • Proceeds to fund R&D for late-stage programs, US commercialization, and working capital

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access